Gene · 7372
Papers1,811
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
41 to 60 of 1,811
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Comprehensive Profiling and Therapeutic Insights into Differentially Expressed Genes in Hepatocellular Carcinoma. | Cancers (Basel) | 2023 | 38067357 | PubTator, text mining | PubMed |
| Methylmalonyl Coenzyme A (CoA) Epimerase Deficiency, an Ultra-Rare Cause of Isolated Methylmalonic Aciduria With Predominant Neurological Features. | Cureus | 2023 | 38034150 | PubTator, text mining | PubMed |
| NAD+ regulates nucleotide metabolism and genomic DNA replication. | Nat Cell Biol | 2023 | 37957325 | PubTator, text mining | PubMed |
| The Strange Case of Orotic Acid: The Different Expression of Pyrimidines Biosynthesis in Healthy Males and Females. | J Pers Med | 2023 | 37888054 | PubTator, text mining | PubMed |
| Use of patient-derived explants as a preclinical model for precision medicine in colorectal cancer: A scoping review. | Langenbecks Arch Surg | 2023 | 37816905 | PubTator, text mining | PubMed |
| A conserved metabolic signature associated with response to fast-acting anti-malarial agents. | Microbiol Spectr | 2023 | 37800971 | PubTator, text mining | PubMed |
| Hypoxanthine phosphoribosyl transferase 1 metabolizes temozolomide to activate AMPK for driving chemoresistance of glioblastomas. | Nat Commun | 2023 | 37737247 | PubTator, text mining | PubMed |
| Cell-specific genome-scale metabolic modeling of SARS-CoV-2-infected lung to identify antiviral enzymes. | FEBS Open Bio | 2023 | 37734920 | PubTator, text mining | PubMed |
| The biological principles and advanced applications of DSB repair in CRISPR-mediated yeast genome editing. | Synth Syst Biotechnol | 2023 | 37711546 | PubTator, text mining | PubMed |
| Nucleoside analogs NM107 and AT-527 are antiviral against rubella virus. | PNAS Nexus | 2023 | 37674858 | PubTator, text mining | PubMed |
| Pyrimidine metabolism regulator-mediated molecular subtypes display tumor microenvironmental hallmarks and assist precision treatment in bladder cancer. | Front Oncol | 2023 | 37664033 | PubTator, text mining | PubMed |
| Recent Advances in the Development of Pyrazole Derivatives as Anticancer Agents. | Int J Mol Sci | 2023 | 37628906 | PubTator, text mining | PubMed |
| Purine Nucleotide Alterations in Tumoral Cell Lines Maintained with Physiological Levels of Folic Acid. | Int J Mol Sci | 2023 | 37628755 | PubTator, text mining | PubMed |
| Integrated Multi-Omics Analysis for Inferring Molecular Players in Inclusion Body Myositis. | Antioxidants (Basel) | 2023 | 37627634 | PubTator, text mining | PubMed |
| Phase II trial of daily S-1 combined with weekly irinotecan in previously treated patients with advanced or recurrent squamous cell lung cancer: North Japan lung cancer group 1101. | Thorac Cancer | 2023 | 37589158 | PubTator, text mining | PubMed |
| De novo nucleotide biosynthetic pathway and cancer. | Genes Dis | 2023 | 37554216 | PubTator, text mining | PubMed |
| Gain-of-function mutant p53 together with ERG proto-oncogene drive prostate cancer by beta-catenin activation and pyrimidine synthesis. | Nat Commun | 2023 | 37537199 | PubTator, text mining | PubMed |
| Metabolic modelling-based in silico drug target prediction identifies six novel repurposable drugs for melanoma. | Cell Death Dis | 2023 | 37495601 | PubTator, text mining | PubMed |
| Review of 5-FU resistance mechanisms in colorectal cancer: clinical significance of attenuated on-target effects. | Cancer Drug Resist | 2023 | 37457133 | PubTator, text mining | PubMed |
| Phase II Trial of Trifluridine/Tipiracil Plus Irinotecan in Patients with Advanced, Refractory Biliary Tract Carcinoma. | Oncologist | 2023 | 37339254 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/7372/papers?page=3